ZHONGSHENGYAOYE's subsidiary has obtained ethical approval for the Phase III clinical trial of the innovative drug Anglatide granules
I'm PortAI, I can summarize articles.
ZHONGSHENGYAOYE's subsidiary, Guangdong Zhongsheng Ruichuang Biotechnology Co., Ltd., has obtained ethical approval to conduct Phase III clinical trials of the innovative drug Anladiwei granules in children aged 2 to 11 years. This drug is the world's first innovative drug targeting the PB2 subunit of the RNA polymerase of the influenza A virus, and it is expected to be approved for market launch in May 2025
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments